Germany · Delayed Price · Currency is EUR Celon Pharma Statistics
Total Valuation
Celon Pharma has a market cap or net worth of EUR 275.05 million. The enterprise value is 273.53 million.
| Market Cap | 275.05M |
| Enterprise Value | 273.53M |
Important Dates
The last earnings date was Wednesday, November 19, 2025.
| Earnings Date | Nov 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 38.86M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.18% |
| Shares Change (QoQ) | -2.57% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 13.30% |
| Float | 23.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.11 |
| PB Ratio | 3.02 |
| P/TBV Ratio | 3.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 2,481.24 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.54 |
| EV / Sales | 5.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -28.31 |
Financial Position
The company has a current ratio of 1.90, with a Debt / Equity ratio of 0.04.
| Current Ratio | 1.90 |
| Quick Ratio | 1.40 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.34 |
| Interest Coverage | -34.42 |
Financial Efficiency
Return on equity (ROE) is -27.03% and return on invested capital (ROIC) is -14.97%.
| Return on Equity (ROE) | -27.03% |
| Return on Assets (ROA) | -12.82% |
| Return on Invested Capital (ROIC) | -14.97% |
| Return on Capital Employed (ROCE) | -26.82% |
| Revenue Per Employee | 94,800 |
| Profits Per Employee | -50,498 |
| Employee Count | 558 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 2.82 |
Taxes
| Income Tax | -950,307 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.57% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -19.57% |
| 50-Day Moving Average | 4.91 |
| 200-Day Moving Average | 5.27 |
| Relative Strength Index (RSI) | 49.21 |
| Average Volume (20 Days) | 1 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Celon Pharma had revenue of EUR 53.85 million and -28.68 million in losses. Loss per share was -0.55.
| Revenue | 53.85M |
| Gross Profit | 37.10M |
| Operating Income | -26.21M |
| Pretax Income | -29.63M |
| Net Income | -28.68M |
| EBITDA | -17.15M |
| EBIT | -26.21M |
| Loss Per Share | -0.55 |
Balance Sheet
The company has 4.82 million in cash and 3.33 million in debt, giving a net cash position of 1.50 million.
| Cash & Cash Equivalents | 4.82M |
| Total Debt | 3.33M |
| Net Cash | 1.50M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 91.21M |
| Book Value Per Share | 1.74 |
| Working Capital | 11.43M |
Cash Flow
In the last 12 months, operating cash flow was 110,850 and capital expenditures -9.77 million, giving a free cash flow of -9.66 million.
| Operating Cash Flow | 110,850 |
| Capital Expenditures | -9.77M |
| Free Cash Flow | -9.66M |
| FCF Per Share | n/a |
Margins
Gross margin is 68.90%, with operating and profit margins of -48.67% and -53.27%.
| Gross Margin | 68.90% |
| Operating Margin | -48.67% |
| Pretax Margin | -55.03% |
| Profit Margin | -53.27% |
| EBITDA Margin | -31.86% |
| EBIT Margin | -48.67% |
| FCF Margin | n/a |
Dividends & Yields
Celon Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.18% |
| Shareholder Yield | 1.18% |
| Earnings Yield | -10.43% |
| FCF Yield | -3.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |